^
Association details:
| Biomarker: | PIK3CA E542K |
|---|---|
| Cancer: | Squamous Cell Carcinoma of Head and Neck |
| Drug: | dactolisib (RTB101) (mTOR inhibitor, PI3K inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers
Excerpt:
Due to the lack of HPV-HNSCC cell line models that contain PIK3CA mutations, we developed an HPV-positive PIK3CA-mutated HNSCC patient tumorgraft model (E542K) (Figure 3C) to determine the sensitivity of HPV-positive PIK3CA-mutated HNSCC tumors to PI3K pathway targeting. As shown in Figure 3D, BEZ-235 treatment (at 25mg/kg/day by oral gavage) significantly inhibited the growth of HPV-positive PIK3CA-mutated patient tumorgraft in vivo (P<0.0001).
DOI:
10.1158/2159-8290.CD-13-0103
